Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher. “Biotech was a coiled spring following several quarters of underperformance,” Dr. Terry Smith, ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

SAN JOSE — Zebra Technologies and bioMerieux reported to the state Employment Development Department their separate decisions to cut jobs in moves that will eliminate a combined 196 positions in San ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

Bay Area startup ASC Therapeutics filed for bankruptcy on Wednesday, marking the end of the line for the gene and cell therapy researcher even as Health and Human Services Secretary Robert F. Kennedy ...

In addition to the reversion trade factors, the sector has benefited from the steady move down in interest rates in 2025. This has been a tailwind for higher beta areas of the small caps, like small ...

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...